Becton, Dickinson and Company


SKU: BDX Category:


Becton delivered an all-around beat in the recent quarter with a revenue growth of 7.9% or 6.3% organic. The company reported another consecutive quarter of robust financial performance and significant progress in advancing the innovation pipeline. The management team acknowledged the recent FDA 510(k) clearance for the updated BD Alaris infusion system, a significant achievement aligned with the BD2025 initiative. Over two decades, infusion pumps, particularly Alaris, have played a pivotal role in healthcare, revolutionizing medication safety and interoperability with electronic medical records. Today, Alaris continues to evolve with enhanced cybersecurity, wireless capabilities, and features facilitating medication management. With this clearance, the focus shifts to market rollout and upgrading existing systems. Financially, Becton reported strong results, reflecting their strategic execution and growth profile, resulting in an increase in the FY ’23 organic growth rate. They highlighted successful product launches across segments, including the BD Preview 2 system and BD FACSDiscover S8 Cell Sorter. The company also emphasized its ESG efforts, showcasing achievements in energy reduction, healthcare access, and diversity. In summary, Becton continues to demonstrate consistent performance and growth, positioning itself as a leading medical technology company.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!